This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

Medivation estimates, target raised at Credit Suisse. Shares of MDVN now seen reaching $122, according to Deutsche Bank. Estimates also increased, as new pre-chemo data looks impressive. Outperform rating.

Monsanto(MON) estimates, target boosted at BofA/Merrill. Shares of MON now seen reaching $96, according to Bank of America/Merrill Lynch. Company should see higher domestic corn and soybean demand. Buy rating.